Nobuki Sakauchi

This inventor holds 11 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nobuki Sakauchi. Retrieved from https://idiyas.com/inventor/nobuki-sakauchi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 3)

% Patents Active = 54.5

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 8(Granted Patents)

Location History:

Osaka, JP (2011 - 2013)
Fujisawa, JP (2020 - 2022)
Kanagawa, JP (2014 - 2023)

Company Filing History:

11 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2011-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435063 - Nitrogen containing heterocycles as CDK12 inhibitors (2025-10-07),

2. 11584737 - Heterocyclic compound (2023-02-21),

3. 11390634 - Fused heterocyclic compound (2022-07-19),

4. 10981934 - Fused heterocyclic compound (2021-04-20),

5. 10577382 - Fused heterocyclic compound (2020-03-03),

6. 8722662 - Heterocyclic compounds (2014-05-13),

7. 8481569 - Iminopyridine derivatives and use thereof (2013-07-09),

8. 8470816 - Nitrogen-containing heterocyclic compound and use thereof (2013-06-25),

9. 7985863 - Iminopyridine derivatives and uses thereof (2011-07-26),

10. 7985862 - Iminopyridine derivatives and use thereof (2011-07-26),

11. 7982044 - Iminopyridine derivatives and use thereof (2011-07-19),

Title: Nobuki Sakauchi: Innovator in Cancer Therapeutics

Introduction

Nobuki Sakauchi is a prominent inventor based in Fujisawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of 11 patents to his name, Sakauchi's work is recognized for its potential impact on therapeutic strategies.

Latest Patents

Sakauchi's latest patents include innovative compounds such as nitrogen-containing heterocycles that act as CDK12 inhibitors. These compounds are designed to exhibit superior CDK12 inhibitory action, making them promising candidates for use as prophylactic or therapeutic drugs for cancer and related diseases. The compounds are represented by specific formulas, which detail their chemical structure and potential applications.

Career Highlights

Nobuki Sakauchi is currently associated with Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His work at Takeda focuses on advancing cancer therapies through innovative research and development. His expertise in medicinal chemistry has been instrumental in the creation of new therapeutic agents.

Collaborations

Sakauchi collaborates with notable colleagues, including Hiroshi Banno and Koji Ono. Together, they work on various projects aimed at enhancing the efficacy of cancer treatments through innovative drug design.

Conclusion

Nobuki Sakauchi's contributions to cancer therapeutics through his patents and collaborations highlight his role as a key innovator in the pharmaceutical industry. His work continues to pave the way for advancements in cancer treatment options.

Profile summary based on public USPTO records.